Abstract: Provided is a pharmaceutical composition for preventing and treating obesity and muscle loss, containing Rhododendron mucronulatum extract as an active ingredient.

Abstract: Provided is a pharmaceutical composition for anti-obesity and preventing or treating muscle loss, which contains an extract of a plant in the genus Ulmus as an active ingredient.

Abstract: The present invention relates to a composition for ameliorating, preventing or treating alopecia, comprising a catechin 7-O-?-D-apiofuranoside compound as an active ingredient. The compound of the present invention inhibits the production of dihydrotestosterone (DHT) converted from testosterone by 5-alpha-reductase in human-derived dermal papilla cells, and inhibits the apoptosis induced by oxidative stress in dermal papilla cells, and accordingly, can be used as an active ingredient for the treatment, prevention, or amelioration purposes.

Abstract: The present disclosure relates to a composition for regulating prostasome secretion, comprising an intracellular calcium signaling second messenger or a regulator thereof. The techniques to promote and regulate the prostasome secretion according to the present disclosure is mainly characterized by providing techniques for regulating exosome secretion based on the signaling mechanism in prostate cells. In particular, since it can directly regulate the secretion of prostasome that imparts motility to the sperm, it can he used for the verification of sperm motility in the diagnosis or treatment of infertility and can be used for the improvement of fertility and for contraception.

Abstract: The present invention relates to a composition for treating a bacterial infection comprising an extract from a bark of Alnus pendula, or diarylheptanoid compound as an active ingredient. The extract from a bark of Alnus pendula, diarylheptanoid compound of the present composition has a remarkably excellent anti-bacterial activity against bacteria, specifically Staphylococcus aureus. Therefore, the extract and compound of the present invention may be utilized as an active ingredient of drug, cosmetics, functional food and animal feed for treating bacterial infection, in particular an infection of S. aureus.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g., IL-4, IL-5 and IL-13) associated with atopic dermatitis. In addition, hirsutenone decreases COX-2 and iNOS expression. Hirsutenone as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis or relieving a symptom of atopic dermatitis.

Abstract: The present invention relates to a composition for treating a bacterial infection comprising an extract from a bark of Alnus pendula, or diarylheptanoid compound as an active ingredient. The extract from a bark of Alnus pendula, diarylheptanoid compound of the present composition has a remarkably excellent anti-bacterial activity against bacteria, specifically Staphylococcus aureus. Therefore, the extract and compound of the present invention may be utilized as an active ingredient of drug, cosmetics, functional food and animal feed for treating bacterial infection, in particular an infection of S. aureus.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutenone as an active ingredient. Hirsutenone as the active ingredient of the present composition decreases the number of eosinophil and the level of IgE increased in atopic dermatitis and remarkably reduces expression amounts of immune regulatory cytokine (e.g., IL-4, IL-5 and IL-13) associated with atopic dermatitis. In addition, hirsutenone decreases COX-2 and iNOS expression. Hirsutenone as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis or relieving a symptom of atopic dermatitis.

Abstract: The present invention relates to a composition for treating atopic dermatitis comprising hirsutanonol as an active ingredient. Hirsutanonol or oregonin as the active ingredient of the present composition decreases the number of eosinophil increased in atopic dermatitis and regulates expression amounts of immune regulatory cytokines, IL-4, IL-5, IL-10 and IL-13 associated with atopic dermatitis. In addition, hirsutanonol and oregonin increase MBD (mouse beta-defensin)-1, MBD-2 and MBD-3 expression and decrease COX-2 and iNOS expression in mouse animal model of atopic dermatitis. Hirsutanonol and oregonin as the active ingredient of the present composition could be effectively used in drugs, cosmetics and foods for treating atopic dermatitis.